Neuropathic Ocular Pain Market Size is expected to increase with a significant CAGR of 5.2% contributing to projected launch of emerging therapies by 2034, estimates DelveInsight

DelveInsight's "Neuropathic Ocular Pain Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the NOP, historical and forecasted epidemiology as well as the NOP market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Neuropathic Ocular Pain Market with DelveInsight's In-Depth Report @ Neuropathic Ocular Pain Market Size [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuropathic Ocular Pain Market Report

* In 2023, the total number of Neuropathic Ocular Pain (NOP) cases across various eye disorders and surgeries was estimated to be around 3,075 thousand in the 7MM, with expectations for this figure to rise by 2034.
* In 2023, the Neuropathic Ocular Pain (NOP) market consists of off-label therapies that provide only temporary and nonspecific relief, leading to an estimated market size of around USD 100 million across the 7MM.
* In DelveInsight's evaluation, Japan reported a total of 3,352 thousand cases of various eye disorders in 2023. Among these, severe Dry Eye Disease accounted for 36%, post-operative complications made up 13%, cataract surgery represented 29%, and other conditions, including infections, systemic diseases, and various ocular surface disorders, constituted 21%.
* In 2023, the EU4 and the UK represented about 1,625 thousand cases of neuropathic ocular pain within the 7MM. Among the European nations, Italy reported the highest incidence, with approximately 535 thousand cases, while France followed with nearly 350 thousand cases.
* According to DelveInsight's projections for 2023, the EU4 and the UK represent 44% of the total cases of various eye disorders and surgeries across the 7MM, exceeding the US at 38% and Japan at 18%. These figures are anticipated to increase during the forecast period from 2024 to 2034, signaling a projected rise in the prevalence of these conditions.
* The leading Neuropathic Ocular Pain Companies such as Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
* Promising Neuropathic Ocular Pain Therapies such as SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others

Stay ahead in the Neuropathic Ocular Pain Therapeutics Market with DelveInsight's Strategic Report @ Neuropathic Ocular Pain Market Outlook [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuropathic Ocular Pain Epidemiology Segmentation in the 7MM

* Total Prevalence of Neuropathic Ocular Pain
* Prevalent Cases of Neuropathic Ocular Pain by severity
* Gender-specific Prevalence of Neuropathic Ocular Pain
* Diagnosed Cases of Episodic and Chronic Neuropathic Ocular Pain

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends @ Neuropathic Ocular Pain Prevalence [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Emerging Neuropathic Ocular Pain Drugs

* OK-101: OKYO Pharma Limited

OK-101, developed by OKYA Pharma, represents a promising therapeutic approach for neuropathic corneal pain (NCP), a condition characterized by chronic pain in the cornea in response to stimuli that are normally non-painful. OK-101 is designed to target the underlying pathophysiological mechanisms of NCP, aiming to provide relief by addressing the specific nerve pain pathways involved in this disorder.

OK-101 is a selective ion channel modulator designed to address neuropathic corneal pain (NOP) by altering nerve signal transmission. This novel approach aims to provide more effective and targeted relief compared to existing treatments, which often offer only temporary relief for NOP. As clinical trials advance, OK-101 could significantly enhance management strategies for NOP, addressing a critical gap in effective, long-lasting pain relief.

Neuropathic Ocular Pain Market Outlook

Current treatments for neuropathic ocular pain (NOP) encompass both pharmacological and non-pharmacological approaches. Pharmacological options include topical anesthetics, such as lidocaine and tetracaine, which provide temporary relief by numbing the corneal surface. Additionally, nerve growth factor (NGF) inhibitors, like cenegermin, are used to promote corneal healing and alleviate pain by targeting underlying nerve damage. Antidepressants, such as amitriptyline, and anticonvulsants, like gabapentin, are sometimes prescribed off-label to manage chronic pain through their central pain-modulating effects

Get In-Depth Knowledge on Neuropathic Ocular Pain Market Trends and Forecasts with DelveInsight @ Neuropathic Ocular Pain Treatment Market [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuropathic Ocular Pain Treatment Market

The pipeline for neuropathic ocular pain (NOP) treatments is notably limited. Few drug candidates are currently under development, reflecting the significant gap in addressing this condition. Despite ongoing research, the lack of innovative therapies means that effective, long-term solutions for NOP remain sparse, underscoring the urgent need for advancements in this area. However the pharmaceutical landscape is expected to evolve with ongoing clinical trials exploring novel treatments, including OK-101, and other drugs. Despite the absence of curative options, advancements in research and development, alongside a comprehensive approach is crucial for addressing the unmet needs in NOP treatment.

Neuropathic Ocular Pain Therapies and Companies

* SAF312: Novartis
* OK-201: OKYO Pharma
* Lidocaine: Aciex Therapeutics
* Ketamine: Novaliq
* Nerve stimulation: Oculeve and Allergan
* Gene Therapy: Adverum Biotechnologies and MeiraGTx
* Gabapentin: Ocular Therapeutix
* Pregabalin: Aldeyra Therapeutics

Unlock Strategic Insights with DelveInsight's Comprehensive Neuropathic Ocular Pain Market Report @ Neuropathic Ocular Pain Market Drivers and Barriers [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuropathic Ocular Pain Market Report

* Study Period: 2020-2034
* Coverage: 7MM
* Neuropathic Ocular Pain Companies: Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies, MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Ltd., SALVAT, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care., Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals, BRIM Biotechnology, Inc., and others
* Neuropathic Ocular Pain Therapies: SAF312, OK-201, Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Neuropathic Ocular Pain Unmet Needs, KOL's views, Analyst's views, Neuropathic Ocular Pain Market Access and Reimbursement

Table of Contents

1. Neuropathic Ocular Pain Market Report Introduction

2. Executive Summary for Neuropathic Ocular Pain

3. SWOT analysis of Neuropathic Ocular Pain

4. Neuropathic Ocular Pain Patient Share (%) Overview at a Glance

5. Neuropathic Ocular Pain Market Overview at a Glance

6. Neuropathic Ocular Pain Disease Background and Overview

7. Neuropathic Ocular Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuropathic Ocular Pain

9. Neuropathic Ocular Pain Current Treatment and Medical Practices

10. Neuropathic Ocular Pain Unmet Needs

11. Neuropathic Ocular Pain Emerging Therapies

12. Neuropathic Ocular Pain Market Outlook

13. Country-Wise Neuropathic Ocular Pain Market Analysis (2020-2034)

14. Neuropathic Ocular Pain Market Access and Reimbursement of Therapies

15. Neuropathic Ocular Pain Market Drivers

16. Neuropathic Ocular Pain Market Barriers

17. Neuropathic Ocular Pain Appendix

18. Neuropathic Ocular Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuropathic-ocular-pain-market-size-is-expected-to-increase-with-a-significant-cagr-of-52-contributing-to-projected-launch-of-emerging-therapies-by-2034-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.